StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research note released on Sunday morning. The firm issued a hold rating on the stock.
Separately, HC Wainwright dropped their price objective on shares of DBV Technologies from $20.00 to $10.00 and set a buy rating on the stock in a research note on Wednesday, May 8th.
Get Our Latest Report on DBV Technologies
DBV Technologies Price Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The business had revenue of $1.41 million during the quarter, compared to the consensus estimate of $3.20 million. On average, equities research analysts expect that DBV Technologies will post -1.22 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
- Five stocks we like better than DBV Technologies
- Most active stocks: Dollar volume vs share volume
- Micron Technology Stock Volatile Despite Analyst Upgrades
- Market Cap Calculator: How to Calculate Market Cap
- McDonald’s Stock: Balancing Value and Innovation
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 6/17 – 6/21
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.